Cargando…

Dendritic Nanotheranostic for the Delivery of Infliximab: A Potential Carrier in Rheumatoid Arthritis Therapy

Antibodies are macromolecules that specifically recognize their target, making them good candidates to be employed in various therapies. The possibility of attaching a drug to an immunoglobulin makes it possible to release it specifically into the affected tissue as long as it overexpresses the targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodríguez-Prieto, Tamara, Hernández-Breijo, Borja, Ortega, Miguel A., Gómez, Rafael, Sánchez-Nieves, Javier, Guijarro, Luis G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730034/ https://www.ncbi.nlm.nih.gov/pubmed/33266032 http://dx.doi.org/10.3390/ijms21239101

Ejemplares similares

Ceria-based nanotheranostic agent for rheumatoid arthritis
por: Kalashnikova, Irina, et al.
Publicado: (2020)

Infliximab in the treatment of rheumatoid arthritis
por: Perdriger, A
Publicado: (2009)

How does infliximab work in rheumatoid arthritis?
por: Maini, Ravinder N, et al.
Publicado: (2002)

Infliximab improves vascular stiffness in patients with rheumatoid arthritis
por: Wong, M, et al.
Publicado: (2008)

Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab
por: Richez, Christophe, et al.
Publicado: (2009)

Cancer nanotheranostics
por: Gopinath, P, et al.
Publicado: (2015)

Introduction to nanotheranostics
por: Tamil Selvan, Subramanian, et al.
Publicado: (2016)

Supramolecular Nanotheranostics
por: Chen, Xiaoyuan, et al.
Publicado: (2019)

A systematic review of infliximab in the treatment of early rheumatoid arthritis
por: Du Pan, Sophie Martin, et al.
Publicado: (2007)

The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients
por: Dwivedi, Ravi C, et al.
Publicado: (2009)

Carbon Nanotubes—Potent Carriers for Targeted Drug Delivery in Rheumatoid Arthritis
por: Kofoed Andersen, Camilla, et al.
Publicado: (2021)

Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study
por: Ortea, Ignacio, et al.
Publicado: (2016)

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
por: Bobbio-Pallavicini, Francesca, et al.
Publicado: (2004)

Rheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
por: Solehan, Hana Maizuliana bt, et al.
Publicado: (2011)

Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
por: Mulleman, Denis, et al.
Publicado: (2009)

Serum ghrelin in female patients with rheumatoid arthritis during treatment with infliximab
por: Magiera, Michal, et al.
Publicado: (2011)

Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab
por: Dénarié, Delphine, et al.
Publicado: (2017)

Casual effect of methotrexate+etanercept/infliximab on survival of patients with rheumatoid arthritis
por: Akhlaghi, Saeed, et al.
Publicado: (2019)

Recurrent and refractory corneal perforation secondary to rheumatoid arthritis treated with infliximab
por: Al Saleh, Ahmed, et al.
Publicado: (2021)

Nanotheranostics for cancer applications
por: Rai, Prakash, et al.
Publicado: (2018)

MXenes in Cancer Nanotheranostics
por: Iravani, Siavash, et al.
Publicado: (2022)

Methotrexate Reduces the Probability of Discontinuation of TNF Inhibitors in Seropositive Patients With Rheumatoid Arthritis. A Real-World Data Analysis
por: Hernández-Breijo, Borja, et al.
Publicado: (2021)

Image-guided drug delivery of nanotheranostics for targeted lung cancer therapy
por: Yin, Xiaoran, et al.
Publicado: (2022)

Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis
por: Hernández-Breijo, Borja, et al.
Publicado: (2022)

Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
por: Lequerré, Thierry, et al.
Publicado: (2006)

An Eight-Gene Blood Expression Profile Predicts the Response to Infliximab in Rheumatoid Arthritis
por: Julià, Antonio, et al.
Publicado: (2009)

Dynamics of longitudinal growth in children with idiopathic rheumatoid arthritis in response to infliximab treatment
por: Konopelko, OU, et al.
Publicado: (2011)

Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis
por: Di Micco, Pierpaolo, et al.
Publicado: (2009)

74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
por: Delabaye, Isabelle, et al.
Publicado: (2010)

Influence of Infliximab on Cytokines Network and Markers of Bone Remodeling in Rheumatoid Arthritis Patients
por: Korczowska, Izabela, et al.
Publicado: (2013)

Segmental vitiligo after infliximab use for rheumatoid arthritis - A case report
por: Carvalho, Clarissa Luiza Dalla Bernardina, et al.
Publicado: (2014)

Ramsay Hunt Syndrome in a Patient with Rheumatoid Arthritis after Treatment with Infliximab
por: Nagayama, Yoshio, et al.
Publicado: (2014)

Biologic-free remission by orthopaedic surgery in non-responder to infliximab for rheumatoid arthritis
por: Kanbe, Katsuaki, et al.
Publicado: (2015)

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
por: Bray, Vance J., et al.
Publicado: (2018)

Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy
por: Lu, Yun-Chi, et al.
Publicado: (2019)

Predictive Value of Serum Infliximab Levels at Induction Phase in Rheumatoid Arthritis Patients
por: Jurado, Teresa, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
por: Gholami, Ahmad, et al.
Publicado: (2021)

Infliximab microencapsulation: an innovative approach for intra-articular administration of biologics in the management of rheumatoid arthritis—in vitro evaluation
por: Lamela-Gómez, Iván, et al.
Publicado: (2023)

Dendritic cell subsets in rheumatoid arthritis
por: Summers, K, et al.
Publicado: (2001)

Progress in the Development of Nanotheranostic Systems
por: Cui, Honggang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dmo7h8su870nh8e5b9csjm8iij